Pharma companies spend more after Phase II
- Book ID
- 104411216
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 34 KB
- Volume
- 2005
- Category
- Article
- ISSN
- 1365-6937
No coin nor oath required. For personal study only.
✦ Synopsis
Filtration Industry Analyst development, measurement, multi-scale modelling and information technology, and a variety of research links, 'IntelliSense' will help produce a next generation of sensors and control solutions, the companies claim.
PHARMA
COMPANIES SPEND MORE AFTER PHASE II
According to a recent report, "Pharmaceutical Product Commercialization: Pre-Clinical to Phase III Resource Allocation" published by Cutting Edge Information, based in North Carolina, USA, when a brand reaches Phase II of development, pharmaceutical companies begin to pour more money into commercial spending.
Commercial spending and staffing stays in check in preclinical through Phase I development, the report suggests. Companies tend to be more cautious with staffing and funds during these early stages regardless of whether they are promoting a future blockbuster drug or a small, niche brand.
However, once developers begin to feel comfortable with their drugs' clinical performance, commercial outlook, and peak sales projections (this usually happens around Phase II), spending and staffing rise substantially, the report says. At this point it becomes obvious which companies plan to promote a blockbuster and which companies are expecting to release a smaller brand. The difference in commercial spending between average blockbuster and niche brands in Phase II is US$7.29 million.
"By Phase II, when drug developers begin to understand their brands' clinical and commercial strengths and weaknesses, companies tend to spend more in line with their drug's commercial prospects or shortcomings," says Jon Hess, project team leader at Cutting Edge Information.